secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2024-10-11T23:59:59+00:00
Accession:  0001193125-24-236782
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma enters ATM sales agreement for up to $75 million common stock offering
--------------------------------------------------------------------------------

- Up to $75M in common stock may be sold at-the-market through agent Leerink Partners.
- Agent commission of 3.0% of gross proceeds; Company to reimburse certain expenses.
- Net proceeds to fund product candidate development, working capital, and general corporate purposes.
- Sales under existing shelf registration statement (S-3) filed March 5, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524236782/0001193125-24-236782-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524236782/d835769d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-236782

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer